Valneva Terminates its Agreement with GSK for Regaining Control of Research and Development Assets

Shots:

• GSK to receive $10.6M as termination fees and up to $7.907M as regulatory milestone for its VLA15. Valneva to regain complete control of its R&D assets including its Lyme vaccine candidate, VLA15
• In 2007, Novartis & Intercell collaborated to accelerate vaccine for infectious diseases. Later, Intercell merged with Valneva in 2013, Novartis divested its global vaccine business (excluding influenza vaccines) to GSK in 2015
• Valneva’s VLA15 is a multivalent vaccine targeting the outer surface protein A (OspA) of Borrelia, being evaluated in P-II study and has received FDA’ s Fast Track designation. Valneva is developing VLA1553, a vaccine for chikungunya and has also received FT designation by FDA

Click here to read full press release/ article | Ref: GlobeNewsWire | Image: Valneva